Pathological Complete Response to Nab-Paclitaxel–Containing Neoadjuvant Regimens in Early Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
Rasha Aziz Attia Salama, Mohamed El-Tanani, Syed Arman Rabbani, Mohamedanas Patni, Bhoomendra Bhongade, Rasha Babiker, Shakta Mani Satyam, Imran Rashid Rangraze, Adil Farooq Wali, Sirajunisa Talath, Omer Eladil Abdalla, Lorenzo Scardina · 2026
Read Pathological Complete Response to Nab-Paclitaxel–Containing Neoadjuvant Regimens in Early Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis by Rasha Aziz Attia Salama, Mohamed El-Tanani, Syed Arman Rabbani, Mohamedanas Patni, Bhoomendra Bhongade, Rasha Babiker, Shakta Mani Satyam, Imran Rashid Rangraze, Adil Farooq Wali, Sirajunisa Talath, Omer Eladil Abdalla, Lorenzo Scardina (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13608542.txt.
Description
Rasha Aziz Attia Salama leads a twelve-author team pooling trial results for one breast cancer regimen question. Triple-negative breast cancer is aggressive and short on targeted drugs, so chemotherapy before surgery is standard. Complete disappearance of the tumor, called pathological complete response, predicts better survival. The team gathered studies of pre-surgery treatment built on nab-paclitaxel, a packaged form of paclitaxel, with platinum drugs and/or checkpoint inhibitors.
Twenty-one studies qualified. Four randomized trials of checkpoint inhibitor addition, covering 1,228 patients, pooled to a risk ratio of 1.25 for complete response, favoring the added immune drug. Fourteen single-arm datasets covering 539 patients pooled to a complete response rate of 59.8 percent. This second figure only describes those cohorts and cannot rank treatments, the authors warn. Their conclusion stays narrow: adding checkpoint blockade improved complete response in the randomized comparisons.
Catalog record
| CREATOR | Rasha Aziz Attia Salama, Mohamed El-Tanani, Syed Arman Rabbani, Mohamedanas Patni, Bhoomendra Bhongade, Rasha Babiker, Shakta Mani Satyam, Imran Rashid Rangraze, Adil Farooq Wali, Sirajunisa Talath, Omer Eladil Abdalla, Lorenzo Scardina |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |